RestoredCDC.org Comparison

    Original site: www.cdc.gov/radiation-emergencies/hcp/clinical-care/neupogen.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.
    [More]
    About Us Report Bug Compare Content
  Skip directly to site content Skip directly to search Skip directly to On This Page
          An official website of the United States government
        Here's how you know
              Official websites use .gov
              A .gov website belongs to an official government organization in the United States.
              Secure .gov websites use HTTPS
              A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
        Radiation Emergencies
          Explore Topics
        Search
          Search
          Clear Input
        For Everyone
          * About Radiation Emergencies
          * Signs and Symptoms
          * Contamination versus Exposure
          * Prevention
          * Preparing for a Radiation Emergency
          * What to Do in Radiation Emergencies
          * Treatment
          * Caring for Yourself and Others
          * View all
        Health Care Providers
          * "Just-In-Time" Resource for Hospitals
          * Clinical Guidance and Resources
          * ICCR Application
          * Clinical Care and Treatment
          * Radiological Terrorism: Emergency Services Clinicians Toolkit
          * Training Resources for Clinicians
          * Radioactive Isotopes
          * View all
        Public Health
          * Radiological Terrorism: Public Health Officials Toolkit
          * Training
          * Communication and Media Tools
          * This is a TEST: Community Reception Center (CRC)
          * Radiation Resource Library
          * Public Health Preparedness Capabilities
          * Information for Public Health Professionals
          * Population Monitoring
          * View all
        View All
      search close search
          search
    Radiation Emergencies Menu Close
    Radiation Emergencies Menu
          search
              For Everyone
                  * About Radiation Emergencies
                  * Signs and Symptoms
                  * Contamination versus Exposure
                  * Prevention
                  * Preparing for a Radiation Emergency
                  * What to Do in Radiation Emergencies
                  * Treatment
                  * Caring for Yourself and Others
                  * View All Home
              Health Care Providers
                  * "Just-In-Time" Resource for Hospitals
                  * Clinical Guidance and Resources
                  * ICCR Application
                  * Clinical Care and Treatment
                  * Radiological Terrorism: Emergency Services Clinicians Toolkit
                  * Training Resources for Clinicians
                  * Radioactive Isotopes
                  * View All
              Public Health
                  * Radiological Terrorism: Public Health Officials Toolkit
                  * Training
                  * Communication and Media Tools
                  * This is a TEST: Community Reception Center (CRC)
                  * Radiation Resource Library
                  * Public Health Preparedness Capabilities
                  * Information for Public Health Professionals
                  * Population Monitoring
                  * View All
        View All Radiation Emergencies
    "Just-In-Time" Resource for Hospitals Clinical Guidance and Resources ICCR Application Clinical Care and Treatment Radiological Terrorism: Emergency Services Clinicians Toolkit Training Resources for Clinicians Radioactive Isotopes View All
April 24, 2024
  Neupogen® (Filgrastim): General Information for Clinicians
          At a glance
          Neupogen® (Filgrastim) is a prescription medication that can help produce white blood cells, making cancer patients less vulnerable to infections. Patients exposed to high levels of radiation may not be able to produce new white blood cells. Neupogen® can speed up the process of creating white blood cells in these patients.
        Overview
        Neupogen® is indicated to decrease the incidence of infection resulting from neutropenia (low white blood cells counts) in cancer patients receiving treatment. Similarly, Neupogen® is also expected to help patients who have bone marrow damage from very high doses of radiation.
        A person who receives a very high dose of penetrating ionizing radiation may experience bone marrow damage, possibly resulting in infection (triggered by neutropenia) and uncontrolled bleeding. A very high dose is greater or equal to 2 Gray (Gy) to the whole body over a short duration.
        Bone marrow suppression occurs with Acute Radiation Syndrome. Medications that speed up blood cell production, including Neupogen, may help the body heal and protect from infections.
        In March 2015, the U.S. Food and Drug Administration (FDA) approved Neupogen® to treat people who have received high doses of radiation.
          Keep Reading: Radiation Contamination Versus Exposure
        How Neupogen® works
        Patients who have been exposed to high doses of radiation will not be able to produce new white blood cells. This leads to a significant decrease in the number of white blood cells (including neutrophils) in circulation. These patients' own bone marrow will eventually create new blood cells, but this process is slow. Until their white blood cell counts rise, these patients are at a high risk of death from infection due to neutropenia.
        Neupogen® can accelerate the process of creating white blood cells. This will reduce the time that the patient is vulnerable to infection.
          Keep Reading: Acute Radiation Syndrome: Information for Clinicians
        Use
        Neupogen® is given to help cancer patients and patients exposed to high doses of radiation produce white blood cells. By producing white blood cells at a faster pace, Neupogen® helps to avoid or minimize the incidence of infections from neutropenia. Neupogen® cannot help the patient in eliminating or blocking the absorption of radioisotopes or any radioactive material from the body.
        Administration
        Who can take Neupogen®?
        Adults and children of all ages can take Neupogen®. This includes pregnant and nursing women if Neupogen® is deemed clinically appropriate. People who have known hypersensitivity to filgrastim, peg-filgrastim, or any component of filgrastim should not take Neupogen®. Components of filgrastim includes E. coli-derived proteins.
        Pregnant women (Category C)
        There is a lack of adequate and well-controlled studies in pregnant women. Some adverse effects have been observed in animal studies. Neupogen® should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
        Nursing mothers
        It is not known whether Neupogen® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised if Neupogen® is administered to women who are breastfeeding.
        Note: Neupogen® is available in single-dose vials and prefilled syringes. The needle cap on the prefilled syringes contains dry natural rubber, derived from latex. People with known severe latex allergies should take precautions when handling or administering Neupogen® from prefilled syringes.
        How is Neupogen® given?
        According to the FDA-approved drug label, the treatment plan for patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of the acute radiation syndrome) is to give 10 micrograms per kilogram of patient weight (10 mcg/kg) daily by subcutaneous injection. Administer Neupogen® as soon as possible after suspected or confirmed exposure to radiation doses greater than 2 gray (Gy).
        The FDA-approved drug label recommends that clinicians obtain a baseline Complete Blood Count (CBC) followed by serial CBCs approximately every third day until the absolute neutrophil count (ANC) remains greater than 1,000/mm3 for three consecutive CBCs. Do not delay administration of Neupogen® if a CBC is not readily available.
        Discontinue Neupogen® therapy until the ANC remains greater than 1,000/mm3 for three consecutive CBCs or greater than 10,000/mm3 after a radiation-induced nadir. The safe use of Neupogen® and duration of Neupogen® treatment will require periodic monitoring of ANC levels as resources permit.
        Side effects
        The most common side effect of Neupogen® is mild to moderate bone pain that may require an analgesic. Other possible side effects of Neupogen® include fever, diarrhea, skin rash and weakness.
        Enlargement and rupture of the spleen can rarely occur in patients who are receiving Neupogen®. Patients who develop abdominal pain, particularly in the left side, or left shoulder pain while receiving the drug should be evaluated as soon as possible.
        Certain serious conditions have been reported in patients receiving Neupogen®:
          * Sickle cell crisis
          * Acute respiratory distress syndrome
          * Splenic ruptures
          * Glomerulonephritis
          * Alveolar hemorrhage and hemoptysis
          * Capillary leak syndrome
          * Thrombocytopenia
          * Leukocytosis
          * Cutaneous vasculitis
          * Serious allergic reactions (i.e., anaphylaxis)
        If any of these conditions are present, discontinue therapy.
        Full information on warnings and precautions.
        Availability
        Neupogen® is commercially available in the marketplace. Use Neupogen® according to the FDA-approved label in patients exposed to high doses of radiation. Neupogen® may be distributed through the Strategic National Stockpile (SNS) when local supplies are depleted or not available during an emergency.
        More detailed information regarding Neupogen® and any emergency use instructions will be provided through state and local public health officials.
        Other information sources
          * FDA Approves Radiation Medical Countermeasure (Neupogen®)
          * REMM: Hematopoietic Subsyndrome of Acute Radiation Syndrome (ARS)
          * Neupogen® Package Insert
        On This Page
            * Overview
            * How Neupogen® works
            * Use
            * Administration
            * Side effects
            * Availability
            * Other information sources
          Related PagesClinical Care and Treatment
          Related Pages
        * 
 
            * Clinical Care and Treatment
            * Clinical Care for Pregnant and Breastfeeding Women
            * ICCR Application
        * 
            * Radiological Terrorism: Emergency Services Clinicians Toolkit
            * Training Resources for Clinicians
        * 
          View All Radiation Emergencies
 
    Radiological Terrorism: Emergency Services Clinicians Toolkit
        Back to Top
  April 24, 2024
      Sources Print Share
        Facebook LinkedIn Twitter Syndicate
          Content Source:
        National Center for Environmental Health
      Related PagesClinical Care and Treatment
      Related Pages
    * 
 
        * Clinical Care and Treatment
        * Clinical Care for Pregnant and Breastfeeding Women
        * ICCR Application
    * 
        * Radiological Terrorism: Emergency Services Clinicians Toolkit
        * Training Resources for Clinicians
    * 
      View All Radiation Emergencies
  Back to Top
    Radiation Emergencies
    Information about how to protect yourself and your family during a radiation emergency.
    View All
        For Everyone
          * About Radiation Emergencies
          * Signs and Symptoms
          * Contamination versus Exposure
          * Prevention
          * Preparing for a Radiation Emergency
          * What to Do in Radiation Emergencies
          * Treatment
          * Caring for Yourself and Others
          * View all
          Health Care Providers
            * "Just-In-Time" Resource for Hospitals
            * Clinical Guidance and Resources
            * ICCR Application
            * View All
          Public Health
            * Radiological Terrorism: Public Health Officials Toolkit
            * Training
            * Communication and Media Tools
            * View All
        Sign up for Email Updates
    Contact Us
        Contact Us
          * Call 800-232-4636
          * Contact CDC
    About CDC
        About CDC
          * Pressroom
          * Organization
          * Budget & Funding
          * Careers & Jobs
    Policies
              * Accessibility
              * External Links
              * Privacy
              * Web Policies
              * FOIA
              * OIG
              * No Fear Act
              * Nondiscrimination
              * Vulnerability Disclosure Policy
    Languages
            Languages
              * Español
            Language Assistance
                  * Español
                  * 繁體中文
                  * Tiếng Việt
                  * 한국어
                  * Tagalog
                  * Русский
                  * العربية
                  * Kreyòl Ayisyen
                  * Français
                  * Polski
                  * Português
                  * Italiano
                  * Deutsch
                  * 日本語
                  * فارسی
                  * English
    Archive
          * CDC Archive
          * Public Health Publications
    Contact Us
      Contact Us
        * Call 800-232-4636
        * Contact CDC
    About CDC
        * Pressroom
        * Organization
        * Budget & Funding
        * Careers & Jobs
        * About CDC
    Policies
        * Accessibility
        * External Links
        * Privacy
        * Web Policies
        * FOIA
        * OIG
        * No Fear Act
        * Nondiscrimination
        * Vulnerability Disclosure Policy
    Languages
      Languages
        * Español
      Language Assistance
        * Español
        * 繁體中文
        * Tiếng Việt
        * 한국어
        * Tagalog
        * Русский
        * العربية
        * Kreyòl Ayisyen
        * Français
        * Polski
        * Português
        * Italiano
        * Deutsch
        * 日本語
        * فارسی
        * English
    Archive
        * CDC Archive
        * Public Health Publications
    HHS.gov USA.gov